Free Trial

BioXcel Therapeutics (BTAI) Stock Forecast & Price Target

$1.21
+0.01 (+0.83%)
(As of 07/12/2024 ET)

BioXcel Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$11.80
875.21% Upside
High Forecast$31.00
Average Forecast$11.80
Low Forecast$4.00
TypeCurrent Forecast
7/13/23 to 7/12/24
1 Month Ago
6/13/23 to 6/12/24
3 Months Ago
4/14/23 to 4/13/24
1 Year Ago
7/13/22 to 7/13/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$11.80$16.71$16.86$37.86
Forecasted Upside875.21% Upside315.68% Upside312.06% Upside127.33% Upside
Get BioXcel Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.

BTAI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BTAI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioXcel Therapeutics Stock vs. The Competition

TypeBioXcel TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.43
2.71
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside875.21% Upside992.53% Upside9.38% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/27/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00+430.30%
5/10/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$10.00+333.84%
3/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$8.00 ➝ $7.00+160.22%
2/21/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Neutral$9.00 ➝ $4.00+13.96%
10/4/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
8/23/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral
7/17/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
3/10/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$20.00 ➝ $22.00-10.42%
1/26/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$16.00 ➝ $26.00-16.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:24 AM ET.

BTAI Forecast - Frequently Asked Questions

What is BioXcel Therapeutics' forecast for 2024?

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for BioXcel Therapeutics is $11.80, with a high forecast of $31.00 and a low forecast of $4.00.

Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.

Does BioXcel Therapeutics's stock price have much upside?

According to analysts, BioXcel Therapeutics's stock has a predicted upside of 342.87% based on their 12-month stock forecasts.

What analysts cover BioXcel Therapeutics?

BioXcel Therapeutics has been rated by research analysts at Canaccord Genuity Group, and HC Wainwright in the past 90 days.

Do Wall Street analysts like BioXcel Therapeutics more than its competitors?

Analysts like BioXcel Therapeutics less than other "medical" companies. The consensus rating for BioXcel Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BTAI compares to other companies.


This page (NASDAQ:BTAI) was last updated on 7/12/2024 by MarketBeat.com Staff

From Our Partners